GSK (GSK) has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday.
The consideration includes $1 billion in an upfront payment, and up to $150 million in potential regulatory-based milestone payments. GSK will also be responsible for milestone and royalty payments owed to Merck KGaA related to IDRX-42, a treatment candidate for gastrointestinal stromal tumors.
The deal is subject to regulatory clearances, and other customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.